Skip to Main Content

The road to find an effective treatment for Alzheimer’s has been long and tortured. Established industry titans have spent many years developing promising drugs, only to see them fail in late-stage trials.

NeuroTherapia Inc., a Cleveland Clinic spinoff, is trying a new approach. Instead of targeting the amyloid plaques thought to contribute to Alzheimer’s disease, NeuroTherapia is focusing on the role of microglia, cells within the central nervous system that cause uncontrolled inflammation.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • Reducing inflammation is a promising approach to Alzheimer’s disease. In addition to drugs that could turn off the inflammatory mechanism, research needs to pay much more attention to the multiple triggers that can turn it on. There is anecdotal evidence there are a wide variety of triggers (for which impacts can vary with genetics), including mercury and aluminum, chemicals and pesticides, molds/mycotoxins, and bacteria and viruses.

Comments are closed.